Panitumumab: A fully human monoclonal antibody with activity in metastatic colorectal cancer

Annals of Pharmacotherapy

Volumn 41, Issue 4, 2007, Pages 606-613

  Saadeh, Claire E ^a,b   Lee, H Stephen ^a,c  

^a FERRIS STATE UNIVERSITY   (United States)

^b Michigan State University and Sparrow Health System   (United States)

^c NONE   (United States)

Author keywords

Colorectal cancer; Panitumumab

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; UNCLASSIFIED DRUG; VECTIBIX;

ABDOMINAL PAIN; ACNE; ANTIBODY PRODUCTION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; NAUSEA; PARONYCHIA; PRIORITY JOURNAL; PRURITUS; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SKIN FISSURE; SKIN TOXICITY; SYSTEMATIC REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; MALE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34247226016     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H492     Document Type: Review

References (35)

1. Cancer facts & figures 2006. Atlanta: American Cancer Society, 2006. www.cancer.org/docroot/stt/stt_0.asp (accessed 2006 Oct 31).
2. Clinical practice guidelines in oncology: colon cancer v.1.2007. Jenkintown, PA: NCCN, 2007. www.nccn.org/professionals/physician_gls/PDF/colon. pdf (accessed 2007 Feb 26).
3. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-87.
4. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005;23:4553-60.
5. Package insert. Avastin (bevacizumab). South San Franciso, CA: Genentech, June 2006.
6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
7. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
8. Package insert. Vectibix (panitumumab). Thousand Oaks, CA: Amgen Inc., September 2006.
9. Ranson M. Technology evaluation: ABX-EGF, Abgenix/Amgen. Curr Opin Mol Ther 2003;5:541-6.
10. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001;38:17-23.
11. Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002;29(suppl):S47-50.
12. Green LL, Hardy MC, Maynard-Currie CE, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 1994;7:13-21.
13. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59:1236-43.
14. Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transduction pathways in colorectal cancer - more than skin deep. J Clin Oncol 2005;23: 5374-85.
15. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65.
16. Vallbohmer D, Lenz HJ. Epidermal growth factor receptor as a target for chemotherapy. Clin Colorectal Cancer 2005;5(suppl):S19-27.
17. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-85.
18. Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 2006;107:1207-18.
19. Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004;58:984-90.
20. Arends R, Yang B, Schwab G, Lockbaum P, Funelas C, Roskos LK. Flexible dosing schedules of panitumumab (ABX-EGF) in cancer patients (abstract). Proc Am Soc Clin Oncol 2005;23:3089.
21. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004;22:3003-15.
22. Figlin R, Belldegrun AS, Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase I clinical results (abstract). Proc Am Soc Clin Oncol 2002;21:35.
23. Weiner LM, Belldegrun AS, Rowinsky EK, et al. Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies (abstract). Proc Am Soc Clin Oncol 2005;23:3059.
24. Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC) (abstract). Proc Am Soc Clin Oncol 2005;23:3520.
25. Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥10% epidermal growth factor receptor (EGFr) (abstract). Proc Am Soc Clin Oncol 2006;24:3548.
26. Hecht JR, Mitchell E, Baranda J, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr) (abstract). Proc Am Soc Clin Oncol 2006;24:3547.
27. Hecht JR, Posey J, Tchekmedyian S, et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC) (abstract). Proc Am Soc Clin Oncol 2006;24:237.
28. Peeters M, Van Cutsem E, Siena S, et al. A phase 3, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (mCRC) (abstract). Am Assoc Cancer Res 2006:CP-1.
29. Wainberg Z, Hecht JR. A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006;5:363-7.
30. Crawford J, Swanson P, Prager D, et al. Panitumumab, a fully human antibody, combined with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for first line advanced non-small cell lung cancer (NSCLC): a primary analysis (abstract 5405). ECCO 2005:(part 2).
31. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-33.
32. Baselga J. Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough? Clin Cancer Res 2003;9:2389-90.
33. Crawford J, Burris H, Stein M, et al. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and gemcitabine/cisplatin (GC) for the treatment of advanced solid malignancies (abstract). Proc Am Soc Clin Oncol 2006;24:13005.
34. Blumenschein G, Sandler A, O'Rourke T, et al. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 2006;24:7119.
35. Package insert. Erbitux (cetuximab). Branchburg, NJ: ImClone Systems and Bristol-Myers Squibb, March 2006.